(October 26, 2016, 12:41 PM EDT) -- WILMINGTON, Del. — An application by Mylan Pharmaceuticals Inc. to market a generic version of the brand-name drug Colcrys would infringe 17 patents, according to a lawsuit filed Oct. 24 in the U.S. District Court for the District of Delaware (Takeda Pharmaceuticals U.S.A. Inc. v. Mylan Pharmaceuticals Inc., No. 16-987, D. Del.).

(Complaint available.  Document #16-161107-019C.)

Takeda Pharmaceuticals U.S.A. Inc. — owner of U.S. patent Nos. 7,906,519, 7,935,731, 8,093,298, 7,964,648, 8,093,297, 7,619,004, 7,601,758, 7,820,681, 7,915,269, 7,964,647, 7,981,938, 8,093,296, 8,097,655, 8,415,395, 8,415,396, 8,440,721 and 8,440,722 — maintains...